Chronic myelogenous leukemia.

[1]  H. Kantarjian,et al.  Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Cortes,et al.  Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial. , 2016, Journal of Clinical Oncology.

[3]  M. Baccarani,et al.  Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Kantarjian,et al.  Practical advice for determining the role of BCR‐ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia , 2011, Cancer.

[5]  Stefan W Krause,et al.  Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Kantarjian,et al.  Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Kantarjian,et al.  Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. , 2011, Blood.

[8]  H. Kantarjian,et al.  Long‐term prognostic impact of the use of erythropoietic‐stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib , 2011, Cancer.

[9]  H. Kantarjian,et al.  Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. , 2011, Blood.

[10]  J. Radich,et al.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. , 2011, Blood.

[11]  J. Goldman,et al.  Three decades of transplantation for chronic myeloid leukemia: what have we learned? , 2011, Blood.

[12]  K. Rezvani,et al.  Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. , 2010, Blood.

[13]  H. Kantarjian,et al.  The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. , 2010, Blood.

[14]  A. Schwarer,et al.  Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial , 2010 .

[15]  J. Cortes,et al.  Lymphocytosis Following First-Line Treatment for CML In Chronic Phase with Dasatinib Is Associated with Improved Responses: A Comparison with Imatinib , 2010 .

[16]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[17]  J. Radich,et al.  Stem cell transplant for chronic myeloid leukemia in the imatinib era. , 2010, Seminars in hematology.

[18]  H. Kantarjian,et al.  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. , 2010, Blood.

[19]  H. Dombret,et al.  Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study , 2010, Cancer.

[20]  H. Kantarjian,et al.  Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR‐ABL kinase domain mutation T315I , 2010, Cancer.

[21]  D. Colomer,et al.  Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group , 2010, Haematologica.

[22]  P. Manley,et al.  Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Z. Estrov,et al.  Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy , 2010, Cancer.

[24]  R. Larson,et al.  Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Cortes,et al.  Association of lymphocytosis following treatment with dasatinib with response and outcome. , 2010 .

[26]  R. Larson,et al.  Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. , 2010 .

[27]  J. Cortes,et al.  Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. , 2010 .

[28]  M. Andreeff,et al.  Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). , 2010 .

[29]  D. Marin,et al.  Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Latagliata,et al.  Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3‐year follow‐up , 2010, American journal of hematology.

[31]  J. Klein,et al.  Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Martin C. Müller,et al.  Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. , 2010, Blood.

[33]  S. Sanabani,et al.  Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy , 2010, Advances in hematology.

[34]  J. Ahn,et al.  Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib , 2010, Annals of Hematology.

[35]  R. Foà,et al.  Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. , 2010, Leukemia research.

[36]  Martin C. Müller,et al.  Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib , 2010, Haematologica.

[37]  D. Marin,et al.  Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia , 2010, Haematologica.

[38]  Susan O'Brien,et al.  Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Susan Branford,et al.  Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Susan O'Brien,et al.  Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Cortes,et al.  Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion , 2010, Cancer.

[42]  J. Melo,et al.  Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? , 2009, Blood.

[43]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Martin C. Müller,et al.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. , 2009, Blood.

[45]  M. Baccarani,et al.  Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. , 2009, Blood.

[46]  C. Carcassi,et al.  Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. , 2009, Blood.

[47]  R. Larson,et al.  High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial , 2009, Haematologica.

[48]  J. Radich,et al.  Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib. , 2009 .

[49]  J. Radich,et al.  International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib , 2009 .

[50]  Martin C. Müller,et al.  Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). , 2009 .

[51]  Z. Estrov,et al.  The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. , 2009, Blood.

[52]  M. Pirmohamed,et al.  Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters , 2009, Leukemia.

[53]  J. Radich.  How I monitor residual disease in chronic myeloid leukemia. , 2009, Blood.

[54]  Babak Shahbaba,et al.  A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. , 2009, Blood.

[55]  S. Sanabani,et al.  Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study , 2009, Journal of hematology & oncology.

[56]  J. Burke,et al.  High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Deininger,et al.  Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. , 2009, Blood.

[58]  H. Kantarjian,et al.  Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily , 2009, Cancer.

[59]  M. Baccarani,et al.  Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. , 2009, Blood.

[60]  H. Kantarjian,et al.  Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. , 2009, Clinical lymphoma & myeloma.

[61]  N. Cross.  Standardisation of molecular monitoring for chronic myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[62]  Martin C. Müller,et al.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  H. Kantarjian,et al.  Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase , 2009, Cancer.

[64]  H. Kantarjian,et al.  Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  V. Ozkocaman,et al.  Imatinib use during pregnancy and breast feeding: a case report and review of the literature , 2009, Archives of Gynecology and Obstetrics.

[66]  H. Kantarjian,et al.  Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. , 2009, Blood.

[67]  H. Kantarjian,et al.  Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia , 2009, Cancer.

[68]  S. Geest,et al.  Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. , 2009, Blood.

[69]  H. Kantarjian,et al.  Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. , 2009, Blood.

[70]  M. Baccarani,et al.  Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Giovanni Martinelli,et al.  Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. , 2009, Blood.

[72]  P. Galieni,et al.  Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. , 2009, Blood.

[73]  H. Kantarjian,et al.  Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. , 2009 .

[74]  R. Larson,et al.  Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase , 2009, Cancer.

[75]  R. Brinkman,et al.  Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. , 2009, Leukemia research.

[76]  M. Baccarani,et al.  The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up , 2009, Haematologica.

[77]  M. Baccarani,et al.  Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response , 2009, Clinical Cancer Research.

[78]  H. Kantarjian,et al.  Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. , 2008, Blood.

[79]  K. Rezvani,et al.  European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. , 2008, Blood.

[80]  M. Baccarani,et al.  Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up , 2008, Haematologica.

[81]  S. Mustjoki,et al.  Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy , 2008, Leukemia.

[82]  H. Kantarjian,et al.  Clinical Use of Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia (CML) , 2008 .

[83]  H. Kantarjian,et al.  Pregnancy Outcomes among Patients with Chronic Myeloid Leukemia Treated with Dasatinib , 2008 .

[84]  M. Baccarani,et al.  Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) , 2008 .

[85]  J. Reynolds,et al.  The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early. , 2008 .

[86]  Z. Rudzki,et al.  The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening , 2008 .

[87]  B. Dörken,et al.  Allogeneic Stem Cell Transplantation (SCT) in Advanced Chronic Myeloid Leukemia (CML) Patients after Tyrosine Kinase Inhibitor (TKI) Therapy , 2008 .

[88]  Martin C. Müller,et al.  Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib. , 2008 .

[89]  H. Kantarjian,et al.  Significance of Rising Levels of Minimal Residual Disease in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+ CML) in Complete Cytogenetic Response (CGCR) , 2008 .

[90]  M. Pirmohamed,et al.  Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. , 2008, Blood.

[91]  A. Zander,et al.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. , 2008, Blood.

[92]  D. Marin,et al.  Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. , 2008, Journal of Clinical Oncology.

[93]  J. Bajpai.  Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial , 2008 .

[94]  H. Kantarjian,et al.  Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. , 2008, Blood.

[95]  J. Cortes,et al.  Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia , 2008, Clinical Cancer Research.

[96]  Jaspal Kaeda,et al.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Andreas Hochhaus,et al.  Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  J. Melo,et al.  Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.

[99]  G. Rosti,et al.  The effects of imatinib on pregnancy outcome. , 2008, Blood.

[100]  M. Baccarani,et al.  Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) , 2008 .

[101]  Tillmann Krahnke,et al.  Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. , 2008, Blood.

[102]  N. Shah,et al.  Advanced CML: therapeutic options for patients in accelerated and blast phases. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[103]  H. Kantarjian,et al.  Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. , 2008, Clinical lymphoma & myeloma.

[104]  J. Radich,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. , 2008, Blood.

[105]  H. Kantarjian,et al.  Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. , 2008, Blood.

[106]  C. Sawyers,et al.  Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. , 2008, Blood.

[107]  M. Pirmohamed,et al.  Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia , 2008, Clinical pharmacology and therapeutics.

[108]  H. Kantarjian,et al.  Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. , 2007, Blood.

[109]  K. Bhalla,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[110]  J. Apperley.  Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.

[111]  B. Druker,et al.  A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response , 2007, Clinical Cancer Research.

[112]  M. Baccarani,et al.  The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells , 2007, Cancer.

[113]  R. Munden,et al.  Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  C. Preudhomme,et al.  Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation , 2007, Haematologica.

[115]  C. Schiffer,et al.  BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. , 2007, The New England journal of medicine.

[116]  H. Kantarjian,et al.  Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia , 2007, Cancer.

[117]  A. Hochhaus,et al.  Advances in the treatment of haematological malignancies: optimal sequence of CML treatment. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[118]  H. Kantarjian,et al.  Current and emerging treatment options in chronic myeloid leukemia , 2007, Cancer.

[119]  H. Heimpel,et al.  Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. , 2007, Blood.

[120]  R. Larson,et al.  Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. , 2007, Blood.

[121]  G. Mufti,et al.  Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy , 2007, British journal of haematology.

[122]  D. Marin,et al.  Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy , 2007, Leukemia.

[123]  M. Baccarani,et al.  Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.

[124]  Nicholas Moore,et al.  Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. , 2007, Blood.

[125]  J. Radich,et al.  Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. , 2007, Blood.

[126]  M. Baccarani,et al.  Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. , 2007, Blood.

[127]  M. Baccarani,et al.  Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. , 2007, Haematologica.

[128]  J. Radich,et al.  The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. , 2007, Blood.

[129]  Z. Estrov,et al.  Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy , 2007, Cancer.

[130]  M. Baccarani,et al.  Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia , 2006, Clinical Cancer Research.

[131]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[132]  H. Kantarjian,et al.  Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.

[133]  J. Reynolds,et al.  Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML. , 2006 .

[134]  H. Kantarjian,et al.  Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate , 2006, Leukemia.

[135]  Susan O'Brien,et al.  Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. , 2006, Blood.

[136]  J. Goldman,et al.  Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia , 2006, Leukemia.

[137]  Tillmann Krahnke,et al.  Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. , 2006, Blood.

[138]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[139]  P. Manley,et al.  OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. , 2006, Blood.

[140]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[141]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[142]  J. Cayuela,et al.  Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP) , 2006, Leukemia.

[143]  M. Baccarani,et al.  Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients , 2006, Clinical Cancer Research.

[144]  H. Kantarjian,et al.  Staging of chronic myeloid leukemia in the imatinib era , 2006, Cancer.

[145]  H. Kantarjian,et al.  Pregnancy among patients with chronic myeloid leukemia treated with imatinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  Hongyue Dai,et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[147]  T. Naoe,et al.  Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice , 2006, Leukemia & lymphoma.

[148]  A. Tefferi,et al.  Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia , 2006, Leukemia & lymphoma.

[149]  K. Prabhash,et al.  Pregnancy outcome of two patients treated with imatinib. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[150]  H. Kantarjian,et al.  Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. , 2005, Blood.

[151]  J. Sierra,et al.  Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. , 2005, Blood.

[152]  W. Siegert,et al.  Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[154]  A. Pathare,et al.  Imatinib in pregnancy , 2005, European journal of haematology.

[155]  D. Marin,et al.  Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib , 2005, Cancer.

[156]  Susan O'Brien,et al.  Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate , 2005, Clinical Cancer Research.

[157]  Munir Pirmohamed,et al.  Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.

[158]  R. Champlin,et al.  Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[159]  R. Herrmann,et al.  Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. , 2004, Blood.

[160]  H. Kantarjian,et al.  Discontinuation of imatinib therapy after achieving a molecular response. , 2004, Blood.

[161]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[162]  G. Flandrin,et al.  Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia , 2004, Leukemia.

[163]  J. Ritz,et al.  Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation , 2004, Clinical Cancer Research.

[164]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[165]  J. Abgrall,et al.  Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. , 2004, Anticancer research.

[166]  H. Kantarjian,et al.  Granulocyte–colony‐stimulating factor (filgrastim) may overcome imatinib‐induced neutropenia in patients with chronic‐phase chronic myelogenous leukemia , 2004, Cancer.

[167]  M. Andreeff,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[168]  R. Stone.  Optimizing treatment of chronic myeloid leukemia: a rational approach. , 2004, The oncologist.

[169]  R. Clark,et al.  Successful Outcome of Pregnancy in Chronic Myeloid Leukaemia Treated with Imatinib , 2004, Leukemia & lymphoma.

[170]  H. Kantarjian,et al.  Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase , 2004, Cancer.

[171]  H. Kantarjian,et al.  High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. , 2004, Blood.

[172]  R. Silver,et al.  Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study , 2004, Leukemia.

[173]  Yi-Ching Hsieh,et al.  Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. , 2004, Blood.

[174]  H. Kantarjian,et al.  Chromosomal abnormalities in Philadelphia chromosome‐negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia in chronic phase , 2003, Cancer.

[175]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[176]  V. Najfeld,et al.  The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. , 2003, Experimental hematology.

[177]  Susan Branford,et al.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.

[178]  J. Zonder,et al.  The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[179]  H. Kantarjian,et al.  Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. , 2003, Blood.

[180]  J. Ford,et al.  Practical management of patients with chronic myeloid leukemia receiving imatinib. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[182]  K. Krohn,et al.  Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. , 2003, Blood.

[183]  A. Nagler,et al.  Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. , 2003, Blood.

[184]  H. Kantarjian,et al.  Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. , 2003, Blood.

[185]  M. Gilleece,et al.  Donor Lymphocyte Infusions for Patients who Relapse After Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia , 2003, Leukemia & lymphoma.

[186]  B. Druker,et al.  The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. , 2002, Blood.

[187]  H. Kantarjian,et al.  Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. , 2002, Blood.

[188]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[189]  E. Winer,et al.  Adherence to therapy with oral antineoplastic agents. , 2002, Journal of the National Cancer Institute.

[190]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[191]  L. Luznik,et al.  Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[192]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[193]  L. Beppu,et al.  The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. , 2001, Blood.

[194]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[195]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[196]  J. Wagner,et al.  Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. , 2001, The American journal of medicine.

[197]  C. Craddock,et al.  Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. , 2001, Blood.

[198]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[199]  M. Varella‐Garcia,et al.  Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.

[200]  Z. Estrov,et al.  The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.

[201]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[202]  J. Hasford,et al.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.

[203]  A. Zinsmeister,et al.  Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. , 1998, Blood.

[204]  C Anasetti,et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.

[205]  G. Utermann,et al.  Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome‐positive chronic myeloid leukemia (CML) during interferon treatment: A new strategy for remission assessment , 1998, Genes, chromosomes & cancer.

[206]  A. Chase,et al.  Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse , 1997, British journal of haematology.

[207]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[208]  M. Horowitz,et al.  Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. , 1996, Bone marrow transplantation.

[209]  L. Barnett,et al.  Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. , 1996, Bone marrow transplantation.

[210]  H. Kantarjian,et al.  Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. , 1995, Blood.

[211]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[212]  A. Elmaagacli,et al.  Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. , 1995, Blood.

[213]  J. Radich,et al.  Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. , 1995, Blood.

[214]  K. Furuse.  [Phase III study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[215]  H. Kantarjian,et al.  Philadelphia chromosome‐negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long term follow‐up results , 1995, Cancer.

[216]  J. Goldman,et al.  Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. , 1994, Bone marrow transplantation.

[217]  Z. Estrov,et al.  Chronic Myelogenous Leukemia : A Concise Update , 2003 .

[218]  J. Ritz,et al.  Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. , 1991, Blood.

[219]  J. Wang,et al.  Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. , 1991, Cancer research.

[220]  Francisco Cervantes,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .

[221]  W. Feng,et al.  Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs , 2012, PharmacoEconomics.

[222]  M. Bissell.  Peripheral Blood Monitoring of Chronic Myeloid Leukemia During Treatment With Imatinib, Second-Line Agents, and Beyond , 2012 .

[223]  J. Cortes,et al.  Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[224]  Martin C. Müller,et al.  Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : an analysis from the International Randomized Study of Interferon and STI 571 ( IRIS ) * , 2010 .

[225]  R. Mahfouz,et al.  Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib , 2010, Archives of Gynecology and Obstetrics.

[226]  M. Gordon.  Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial , 2010 .

[227]  M. Gordon.  Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia , 2010 .

[228]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[229]  T. Hughes,et al.  Monitoring disease response to tyrosine kinase inhibitor therapy in CML. , 2009, Hematology. American Society of Hematology. Education Program.

[230]  A. Nagler,et al.  Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia , 2009, Leukemia.

[231]  J. Radich,et al.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib : 15-month median follow-up , 2009 .

[232]  T. Brümmendorf,et al.  Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase , 2008, Leukemia.

[233]  J. Lipton,et al.  Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. , 2007, Leukemia & lymphoma.

[234]  J. Cayuela,et al.  Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome – positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study , 2007 .

[235]  P. Loehrer.  Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate , 2007 .

[236]  T. Haferlach,et al.  IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. , 2010, Blood.

[237]  V. Choudhry,et al.  Pregnancy on imatinib: fatal outcome with meningocele. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[238]  S. Iacobelli,et al.  Design and Methods , 2022 .

[239]  R. Brand,et al.  Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 2006, Haematologica.

[240]  R. Clark,et al.  The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. , 2006, Haematologica.

[241]  M. Zucchetti,et al.  Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[242]  H. Kantarjian,et al.  Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[243]  H. Kantarjian,et al.  Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. , 2002, Blood.

[244]  B. Druker,et al.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.

[245]  B. Druker.  Current treatment approaches for chronic myelogenous leukemia. , 2001, Cancer Journal.

[246]  Alfred Gangl,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use , 2000 .

[247]  K. Sullivan,et al.  Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. , 1998, Blood.

[248]  J. Gabert,et al.  Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. , 1996, Leukemia & lymphoma.

[249]  H. Kantarjian,et al.  Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[250]  M. Horowitz,et al.  Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. , 1993, Blood.

[251]  D. Ginsburg,et al.  Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. , 1992, Blood.

[252]  M. Baccarani,et al.  Staging and prognosis in chronic myelogenous leukemia. , 1988, Seminars in hematology.

[253]  K. Krohn.  Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses , 2022 .